195.21

0.43% -0.775

Charles River Laboratories International Inc (CRL)

Overview News Price History Option Chain Financials Discussions Forecast

Charles River Laboratories International Inc stock is traded at $195.21, with a volume of 353.79K. It is down -0.43% in the last 24 hours and up +20.06% over the past month. Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Previous Close:

$195.98

Open:

$197.32

24h Volume:

353.79K

Relative Volume:

0.35

Market Cap:

$9.61B

Revenue:

$4.06B

Net Income/Loss:

$413.08M

P/E Ratio:

24.37

EPS:

8.01

Net Cash Flow:

$560.48M

1W Performance:

+0.36%

1M Performance:

+20.06%

6M Performance:

+34.30%

1Y Performance:

+6.54%

1-Day Range:

$193.63

$199.93

1-Week Range:

$192.09

$200.58

52-Week Range:

$91.86

$200.58

Charles River Laboratories International Inc Stock (CRL) Company Profile

Name

Charles River Laboratories International Inc

Sector

Healthcare (1136)

Industry

Diagnostics & Research (54)

Phone

781-222-6000

Address

251 BALLARDVALE ST, WILMINGTON, MA

Employee

20,100

Twitter

@criverlabs

Next Earnings Date

2024-11-06

Latest SEC Filings

CRL's Discussions on Twitter

Compare CRL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRL Charles River Laboratories International Inc	195.21	9.65B	4.06B	413.08M	560.48M	8.01
TMO Thermo Fisher Scientific Inc	562.03	211.36B	43.74B	6.58B	6.11B	17.31
DHR Danaher Corp	225.53	157.25B	24.27B	3.50B	5.02B	4.8589
IDXX Idexx Laboratories Inc	697.08	55.54B	4.17B	1.03B	940.22M	12.61
A Agilent Technologies Inc	137.23	38.68B	6.95B	1.30B	1.15B	4.5714
IQV Iqvia Holdings Inc	223.16	37.71B	15.90B	1.28B	2.21B	7.2842

Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-17-25	Upgrade	Argus	Hold → Buy
Nov-06-25	Upgrade	Robert W. Baird	Neutral → Outperform
Oct-06-25	Upgrade	William Blair	Mkt Perform → Outperform
Oct-02-25	Upgrade	Barclays	Equal Weight → Overweight
Sep-09-25	Upgrade	Jefferies	Hold → Buy
Jul-09-25	Upgrade	Citigroup	Neutral → Buy
May-23-25	Upgrade	Redburn Atlantic	Neutral → Buy
May-14-25	Upgrade	TD Cowen	Hold → Buy
May-08-25	Upgrade	Evercore ISI	In-line → Outperform
Mar-21-25	Downgrade	Goldman	Buy → Neutral
Mar-04-25	Upgrade	Citigroup	Sell → Neutral
Mar-03-25	Upgrade	Redburn Atlantic	Sell → Neutral
Jan-22-25	Downgrade	William Blair	Outperform → Mkt Perform
Jan-17-25	Downgrade	UBS	Buy → Neutral
Nov-18-24	Downgrade	CLSA	Hold → Underperform
Nov-07-24	Upgrade	CLSA	Underperform → Hold
Oct-23-24	Initiated	CLSA	Underperform
Oct-14-24	Initiated	Redburn Atlantic	Sell
Oct-07-24	Downgrade	Evercore ISI	Outperform → In-line
Oct-02-24	Downgrade	BofA Securities	Buy → Neutral
Oct-01-24	Downgrade	Citigroup	Neutral → Sell
Aug-08-24	Downgrade	JP Morgan	Overweight → Neutral
Aug-08-24	Downgrade	Robert W. Baird	Outperform → Neutral
Jun-28-24	Downgrade	Argus	Buy → Hold
Jun-07-24	Initiated	Mizuho	Neutral
Jun-06-24	Initiated	Goldman	Buy
Feb-15-24	Downgrade	Guggenheim	Buy → Neutral
Sep-13-23	Initiated	TD Cowen	Market Perform
Jul-10-23	Downgrade	Citigroup	Buy → Neutral
Feb-23-23	Upgrade	Guggenheim	Neutral → Buy
Jan-12-23	Downgrade	Jefferies	Buy → Hold
Sep-30-22	Upgrade	Jefferies	Hold → Buy
Aug-25-22	Initiated	Credit Suisse	Outperform
Aug-04-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
May-24-22	Initiated	Guggenheim	Neutral
Apr-25-22	Downgrade	Jefferies	Buy → Hold
Apr-07-22	Initiated	Stephens	Overweight
Feb-17-22	Reiterated	BofA Securities	Buy
Feb-17-22	Upgrade	Citigroup	Neutral → Buy
Feb-17-22	Reiterated	Deutsche Bank	Buy
Feb-17-22	Reiterated	Morgan Stanley	Overweight
Feb-17-22	Reiterated	UBS	Buy
Aug-05-21	Resumed	Credit Suisse	Neutral
Dec-16-20	Downgrade	Citigroup	Buy → Neutral
Sep-10-20	Upgrade	Jefferies	Hold → Buy
Jul-01-20	Upgrade	BofA Securities	Neutral → Buy
May-13-20	Upgrade	UBS	Neutral → Buy
Apr-21-20	Downgrade	Jefferies	Buy → Hold
Mar-27-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-02-20	Initiated	Deutsche Bank	Buy
Feb-18-20	Upgrade	Wolfe Research	Peer Perform → Outperform
Jan-10-20	Upgrade	Goldman	Neutral → Buy
Jan-08-20	Initiated	Wells Fargo	Overweight
Jan-07-20	Initiated	Citigroup	Buy
Oct-18-19	Downgrade	BofA/Merrill	Buy → Neutral
Jun-10-19	Initiated	SVB Leerink	Outperform
Apr-30-19	Resumed	Evercore ISI	Outperform
Dec-14-18	Initiated	Deutsche Bank	Buy
Oct-09-18	Initiated	UBS	Neutral
Aug-23-18	Upgrade	Raymond James	Mkt Perform → Outperform
Jul-17-18	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Jun-15-18	Upgrade	KeyBanc Capital Mkts	Sector Weight → Overweight
Feb-14-18	Upgrade	SunTrust	Hold → Buy

View All

Charles River Laboratories International Inc Stock (CRL) Latest News

09:32 AM

Charles River Labs (NYSE:CRL) Shares Little Changed in NYSE Trade - Kalkine Media

09:32 AM

08:55 AM

Mizuho Adjusts Price Target on Charles River Laboratories International to $200 From $174, Maintains Neutral Rating - marketscreener.com

08:55 AM

08:52 AM

Mizuho Issues Positive Forecast for Charles River Laboratories International (NYSE:CRL) Stock Price - MarketBeat

08:52 AM

08:36 AM

Should You Continue to Hold CRL Stock in Your Portfolio for Now? - TradingView — Track All Markets

08:36 AM

Dec 17, 2025

Charles River Laboratories appoints Michael Knell as interim CFO - MSN

Dec 17, 2025

Dec 16, 2025

Is Charles River Laboratories Stock Attractively Priced After Recent Share Price Rebound in 2025? - Yahoo Finance UK

Dec 16, 2025

What Charles River Laboratories International (CRL)'s SEC Clearance and Analyst Upgrades Mean For Shareholders - simplywall.st

Dec 16, 2025

Is Charles River Laboratories Stock Underperforming the Dow? - inkl

Dec 16, 2025

Dec 15, 2025

JP Morgan Maintains Charles River Laboratories International (CRL) Neutral Recommendation - Nasdaq

Dec 15, 2025

Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch

Dec 15, 2025

Charles River Laboratories International (NYSE:CRL) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat

Dec 15, 2025

Charles River Labs (NYSE:CRL) Shares Little Changed on Ownership Focus - Kalkine Media

Dec 15, 2025

Charles River Laboratories International (NYSE:CRL) Reaches New 12-Month High After Analyst Upgrade - MarketBeat

Dec 15, 2025

Barclays Adjusts PT on Charles River Laboratories International to $215 From $210, Keeps Overweight Rating - marketscreener.com

Dec 15, 2025

Charles River Laboratories stock hits 52-week high at 200.51 USD - Investing.com

Dec 15, 2025

Charles River Laboratories International (NYSE:CRL) Upgraded at Bank of America - MarketBeat

Dec 15, 2025

JPMorgan Adjusts Charles River Laboratories International PT to $190 From $165, Maintains Neutral Rating - marketscreener.com

Dec 15, 2025

Charles River Labs stock rating upgraded by BofA on early research exposure - Investing.com

Dec 15, 2025

BofA Securities Upgrades Charles River Laboratories International to Buy - marketscreener.com

Dec 15, 2025

Charles River (CRL) Receives Upgrade Amid Biopharma Market Changes - GuruFocus

Dec 15, 2025

National Bank of Canada FI Boosts Stock Position in Charles River Laboratories International, Inc. $CRL - MarketBeat

Dec 15, 2025

Dec 13, 2025

Assessing Charles River Laboratories (CRL) Valuation as Its Cell & Gene Therapy Incubator Program Expands - simplywall.st

Dec 13, 2025

Charles River Laboratories International (NYSE:CRL) Stock Rating Lowered by Wall Street Zen - MarketBeat

Dec 13, 2025

Dec 12, 2025

Sei Investments Co. Buys 39,959 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat

Dec 12, 2025

Bayesian Capital Management LP Takes Position in Charles River Laboratories International, Inc. $CRL - MarketBeat

Dec 12, 2025

Dec 11, 2025

Charles River Laboratories (CRL): Reassessing Valuation After a Quiet Share Price Rebound - Sahm

Dec 11, 2025

Charles River Extends Commitment to Advanced Therapy Developers with Second Incubator Program Cohort - PharmiWeb.com

Dec 11, 2025

Charles River Announces Latest Cohort of Its Cell & Gene Therapy Incubator Program - Contract Pharma

Dec 11, 2025